Dhiman Ashish, Rana Dhwani, Benival Derajram, Garkhal Kalpna
Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research-Ahmedabad (NIPER-A), Gandhinagar, 382355, Gujarat, India.
Ther Deliv. 2025 Jan;16(1):87-115. doi: 10.1080/20415990.2024.2415281. Epub 2024 Oct 24.
Glioblastoma multiforme (GBM) is one of the most common and malignant brain tumors, with a high prevalence in elderly population. Most chemotherapeutic agents fail to reach the tumor site due to various challenges. However, smart nanocarriers have demonstrated excellent drug-loading capabilities, enabling them to cross the blood brain tumor barrier for the GBM treatment. Surface modification of nanocarriers has significantly enhanced their potential for targeting therapeutics. Moreover, recent innovations in drug therapies, such as the incorporation of theranostic agents in nanocarriers and antibody-drug conjugates, have offered newer insights for both diagnosis and treatment. This review focuses on recent advances in new therapeutic interventions for GBM, with an emphasis on the nanotheranostics systems to maximize therapeutic and diagnostic outcomes.
多形性胶质母细胞瘤（GBM）是最常见的恶性脑肿瘤之一，在老年人群中发病率很高。由于各种挑战，大多数化疗药物无法到达肿瘤部位。然而，智能纳米载体已显示出优异的载药能力，使其能够穿越血脑肿瘤屏障用于GBM治疗。纳米载体的表面修饰显著增强了其靶向治疗的潜力。此外，药物治疗的最新创新，如在纳米载体中加入诊疗剂和抗体药物偶联物，为诊断和治疗提供了新的见解。本综述重点关注GBM新治疗干预措施的最新进展，重点是纳米诊疗系统，以最大限度地提高治疗和诊断效果。
